NIH 's New Approach To Grant Cuts Won't Ease Deficiencies In Funding

While the agency's halt to `downward negotiations' may promote fairness, it fails to brighten overall research support vistas WASHINGTON--The National Institutes of Health has officially ended its highly unpopular practice of applying unilateral, across-the-board cuts to the grants of those researchers it funds. But most scientists will find that the varying approaches adopted by individual institutes to replace what were euphemistically called "downward negotiations" do not yield any more mon

Written byJeffrey Mervis
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

WASHINGTON--The National Institutes of Health has officially ended its highly unpopular practice of applying unilateral, across-the-board cuts to the grants of those researchers it funds. But most scientists will find that the varying approaches adopted by individual institutes to replace what were euphemistically called "downward negotiations" do not yield any more money for their research.

"We have begun to do away with across-the-board cuts," John Diggs, NIH deputy director for extramural research, told the House appropriations committee's labor and health and human services subcommittee last month at hearings on the agency's 1992 proposed budget. "Instead, we're examining specific categories of cuts, to determine whether they are reasonable and allowable." The dramatic shakeups that businesses undertake to solve problems aren't an option for the federal government, in which political considerations can sometimes stifle decisive action. Instead, what the government does when something's not working right is assemble a panel of outside ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies